Huiyu Pharmaceutical: Injection Clofazimine Obtained Drug Registration Certificate

Huiyu Pharmaceutical announced that it has recently received the "Drug Registration Certificate" for the company's product Kanifozomi for injection issued by the National Medical Products Administration. Kanifozomi for injection is mainly used for the treatment of multiple myeloma. The original research product, Kanifozomi for injection, from Onyx Pharmaceuticals, Inc. has already been launched in the domestic market. So far, there are 7 domestic companies that hold approval for Kanifozomi for injection and have passed or are considered to have passed the generic drug quality and efficacy consistency evaluation, including Huiyu Pharmaceutical, Jiangsu Haosen, Qilu Pharmaceutical, Zhengda T